JPWO2020150534A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020150534A5
JPWO2020150534A5 JP2021541429A JP2021541429A JPWO2020150534A5 JP WO2020150534 A5 JPWO2020150534 A5 JP WO2020150534A5 JP 2021541429 A JP2021541429 A JP 2021541429A JP 2021541429 A JP2021541429 A JP 2021541429A JP WO2020150534 A5 JPWO2020150534 A5 JP WO2020150534A5
Authority
JP
Japan
Prior art keywords
gene
cells
gene sequence
immune cells
modified immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518463A5 (https=
JP2022518463A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013964 external-priority patent/WO2020150534A2/en
Publication of JP2022518463A publication Critical patent/JP2022518463A/ja
Publication of JP2022518463A5 publication Critical patent/JP2022518463A5/ja
Publication of JPWO2020150534A5 publication Critical patent/JPWO2020150534A5/ja
Priority to JP2024141710A priority Critical patent/JP2024174899A/ja
Pending legal-status Critical Current

Links

JP2021541429A 2019-01-16 2020-01-16 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞 Pending JP2022518463A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024141710A JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962793277P 2019-01-16 2019-01-16
US62/793,277 2019-01-16
US201962839870P 2019-04-29 2019-04-29
US62/839,870 2019-04-29
PCT/US2020/013964 WO2020150534A2 (en) 2019-01-16 2020-01-16 Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024141710A Division JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Publications (3)

Publication Number Publication Date
JP2022518463A JP2022518463A (ja) 2022-03-15
JP2022518463A5 JP2022518463A5 (https=) 2023-01-25
JPWO2020150534A5 true JPWO2020150534A5 (https=) 2023-01-25

Family

ID=71613446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541429A Pending JP2022518463A (ja) 2019-01-16 2020-01-16 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞
JP2024141710A Pending JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024141710A Pending JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Country Status (9)

Country Link
US (1) US20220133790A1 (https=)
EP (1) EP3911735A4 (https=)
JP (2) JP2022518463A (https=)
KR (1) KR20210116526A (https=)
CN (1) CN114072495A (https=)
AU (1) AU2020208616A1 (https=)
CA (1) CA3126699A1 (https=)
SG (1) SG11202107555XA (https=)
WO (1) WO2020150534A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907870VA (en) 2017-02-28 2019-09-27 Vor Biopharma Inc Compositions and methods for inhibition of lineage specific proteins
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
EP3918077A4 (en) * 2019-01-31 2023-03-29 Beam Therapeutics, Inc. NUCLEOBASE EDITORS WITH REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE TARGET SEQUENCE
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP7831937B2 (ja) * 2019-09-03 2026-03-17 クリエイト・メディシンズ，インコーポレーテッド ゲノム組込みのための方法および組成物
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
US20240238344A1 (en) * 2020-08-28 2024-07-18 Vor Biopharma Inc. Compositions and methods for cd123 modification
WO2022056459A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
CN116322716A (zh) * 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
AU2021347359A1 (en) * 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20230364146A1 (en) * 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
US20250195650A1 (en) * 2020-11-04 2025-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for enhancing efficacy of therapeutic immune cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
CR20230305A (es) * 2020-12-11 2023-11-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
WO2022215978A1 (ko) * 2021-04-05 2022-10-13 주식회사 셀렌진 Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
CN113179160B (zh) * 2021-04-15 2022-03-18 中国电子科技集团公司第三十研究所 一种适用于qkd中私钥放大的最优输入码长处理方法及单元
CA3217458A1 (en) * 2021-05-06 2022-11-10 Spyro Mousses Sirna constructs for inhibiting gene expression in targeted cancer cells
AU2022272235A1 (en) * 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
CA3228879A1 (en) * 2021-08-16 2023-02-23 Beam Therapeutics Inc. Persistent allogeneic modified immune cells and methods of use thereof
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
WO2023034742A1 (en) * 2021-08-30 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University T cells with cell-surface expression of adenosine deaminase and uses thereof
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
CN113980896B (zh) * 2021-10-27 2023-10-20 中国人民解放军军事科学院军事医学研究院 Irf1在调控间充质干细胞免疫调节作用及产品上的应用
EP4426338A2 (en) * 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
CA3240846A1 (en) * 2021-12-14 2023-06-22 The Trustees Of The University Of Pennsylvania Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
EP4532697A2 (en) * 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
WO2024054062A1 (ko) * 2022-09-08 2024-03-14 주식회사 에이조스바이오 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
EP4587570A2 (en) * 2022-09-16 2025-07-23 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
CN120239746A (zh) * 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
JP2025532979A (ja) * 2022-09-30 2025-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 養子ｔ細胞治療薬を増強させるための組成物および方法
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
WO2024186841A2 (en) * 2023-03-06 2024-09-12 La Jolla Institute For Immunology Nfkbid cells and methods for immunotherapy
WO2024193562A1 (zh) * 2023-03-21 2024-09-26 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途
WO2024215414A1 (en) * 2023-04-12 2024-10-17 Beam Therapeutics Inc. Modified immune effector cells with improved efficacy
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
IL324508A (en) * 2023-05-16 2026-01-01 Prime Medicine Inc Genome editing compositions targeting the b2m gene and methods of use
CN121195068A (zh) * 2023-05-26 2025-12-23 爱迪塔斯医药公司 靶向cd70表达的crispr相关方法和组合物
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途
WO2025111533A1 (en) * 2023-11-22 2025-05-30 The General Hospital Corporation Car-t cells comprising a cdkn1b gene knockout and methods of use thereof
WO2025119307A1 (zh) * 2023-12-06 2025-06-12 北京齐禾生科生物科技有限公司 优化的qbe碱基编辑系统及其应用
WO2025122896A1 (en) * 2023-12-08 2025-06-12 The Trustees Of The University Of Pennsylvania Cd5 modified cells comprising heterologous tcrs and methods of using the same
WO2025238594A2 (en) * 2024-05-16 2025-11-20 Fondazione Istituto Italiano Di Tecnologia DESIGN OF SYNTHETIC miRNAS TO RESTORE THE CORRECT GENE DOSAGE OF GENES ASSOCIATED WITH T LYMPHOCYTE EXHAUSTION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
CA3012607A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US20170020922A1 (en) * 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
JP7109784B2 (ja) * 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
EA201891338A1 (ru) * 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
BR112019000057A2 (pt) * 2016-07-05 2019-04-02 The Johns Hopkins University composições e métodos com base em crispr/cas9 para o tratamento de degeneração de retina
CN108753823B (zh) * 2018-06-20 2022-09-23 李广磊 利用碱基编辑技术实现基因敲除的方法及其应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用

Similar Documents

Publication Publication Date Title
JPWO2020150534A5 (https=)
JP2024095667A (ja) リンパ球における高レベル且つ安定な遺伝子移入のための方法
US20240076309A1 (en) Compositions and methods for transient gene therapy with enhanced stability
US11453861B2 (en) Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
CN115279398B (zh) 治疗液态癌症的组合物和方法
AU2023222981A1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
Glaser et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
JP7611564B2 (ja) Ｃａｓ９塩基エディターを使用するリンパ球造血系操作
CA3149897A1 (en) Methods and compositions for genomic integration
JP2024531344A (ja) 持続性同種改変免疫細胞及びそれらの使用方法
WO2017093969A1 (en) Compositions and methods for immunooncology
WO2020176740A1 (en) Improved process for dna integration using rna-guided endonucleases
KR20230044537A (ko) 원하는 표현형을 갖는 car t 세포의 조작 및 선택을 위한 조성물 및 방법
JP2024515936A (ja) Ｃａｓ酵素を用いたマルチプレックス編集
US20250313861A1 (en) Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20250179184A1 (en) Foxp1-ablated chimeric cells
Tretbar et al. Non-viral vectors for chimeric antigen receptor immunotherapy
Arroyo-Olarte et al. Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al.
WO2017217444A1 (ja) 二本鎖ｄｎａ末端の加工方法
WO2022015956A1 (en) Improved process for dna integration using rna-guided endonucleases
WO2025151400A1 (en) Modified immune cells with increased resistance to allorejection
WO2023105000A1 (en) Vector
HK40019066B (en) Compositions and methods for transient gene therapy with enhanced stability
HK40019066A (en) Compositions and methods for transient gene therapy with enhanced stability